We have a proprietary cancer biology platform that has allowed us to develop our clinical-stage small molecule and biologic drug candidates and several additional preclinical-stage drug candidates in potentially important areas, currently consisting of potential targeted therapies and immuno-oncology agents.
As an innovative biotechnology company with research facilities in China, we have been able to attract an internationally-trained research team of more than 380 talented scientists. The team has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support our drug discovery effort.
Immunotherapy has now been established as one of the cornerstones of anticancer treatments. There is tremendous potential for synergistic combinations of cancer immunotherapies and also for combining cancer immunotherapies with targeted therapies. Our preclinical pipeline consists of additional targeted therapies and immuno-oncology agents, all potentially best-in-class or first-in-class.
In addition to our internal research platform, we are actively in pursuit of preclinical and early-stage assets to expand our pipeline and build unique, sustainable competitive advantages.
Evaluating Potential Combinations
To evaluate the potential different combinations, we are using our extensive collection of in vitro, in vivo and ex vivo cancer models. These proprietary models developed in house have elements of a functional immune system integrated through allogeneic, syngeneic and humanization methods.
Preclinical Program Highlights
BGB-15025 – HPK1 inhibitor
BGB-15025 is a potentially first-in-class HPK1 inhibitor. HPK1 is a key negative feedback regulator of TCR signaling. The inhibition of HPK1 can enhance T cell activation and in preclinical animal models, the combination with anti-PD-1 antibody has shown robust anti-tumor activity. The preliminary toxicity study suggests wide therapeutic window of approximately 20 to 50 fold.